Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study
- 15 February 2018
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 90 (5), 951-958
- https://doi.org/10.1002/jmv.25033
Abstract
We report the first real-world prospective multicenter cohort study that evaluated the effectiveness and safety of original or generic sofosbuvir-based regimens in patients with chronic hepatitis C in Latin America. The main endpoints were assessment of sustained virological response and serious adverse events rates. A total of 321 patients with chronic hepatitis C treated with the following regimens were included: sofosbuvir plus daclatasvir for 12 (n = 34) or 24 (n = 135) weeks, sofosbuvir plus daclatasvir plus ribavirin for 12 (n = 84) or 24 (n = 56) weeks, or sofosbuvir plus ribavirin for 12 (n = 8) or 24 (n = 2) weeks. Patients received either original sofosbuvir (Sovaldi®, Gilead Sciences, n = 135) or generic sofosbuvir (Probirase®, Laboratorios RICHMOND, n = 184) which were randomly assigned by the National Ministry of Health. Overall, 292 (91%) patients had cirrhosis, 136 (42%) were treatment experienced, and 240 (75%) genotype 1. The overall sustained virological response was 90% (95% CI 86%-93%); 91% (95% CI 84%-95%) in patients who received Sovaldi®, and 89% (95% CI 84%-93%) in patients who received Probirase®. Anemia was the most common adverse event and was reported in 52 (17%) patients. Bacterial infection, gastrointestinal bleeding, worsening of ascites or encephalopathy occurred in less than 5% of the patients. During the study, seven (2%) patients died, four of whom died of cirrhosis-related complications. In summary, we observed similar sustained virological response rates than prior studies, both in patients who received Sovaldi® or Probirase®. Serious adverse events were infrequent, in line with prior studies that included patients with cirrhosis treated with protease-inhibitor-free regimes. This article is protected by copyright. All rights reservedKeywords
This publication has 20 references indexed in Scilit:
- Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsJournal of Hepatology, 2016
- The use of generic medications for hepatitis CLiver International, 2016
- Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European studyJournal of Hepatology, 2016
- The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirinLiver International, 2016
- Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrenceHepatology, 2016
- High Sustained Virological Response Rates Using Generic Direct Acting Antiviral Treatment for Hepatitis C, Imported into AustraliaJournal of Hepatology, 2016
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseGastroenterology, 2015
- Hepatitis C in Argentina: epidemiology and treatmentHepatic Medicine: Evidence and Research, 2014
- Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013Journal of Hepatology, 2014
- Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertensionJournal of Hepatology, 2010